Dilon Devices Named a TAG Top 40 Innovative Technology Company

By Feb 23, 2018 News

The Technology Association of Georgia (TAG), the state’s leading association dedicated to the promotion and economic advancement of Georgia’s technology industry, today announced Dilon Devices as one of its Top 40 Innovative Technology Companies in Georgia. TAG will recognize this prestigious group at The Summit 2018 on March 20th and 21st, 2018, at the Cobb Galleria Centre.

TAG’S Top 40 Awards recognize Georgia-based technology companies for their innovation, financial impact, and their efforts at spreading awareness of Georgia’s technology initiatives throughout the U.S. and globally. This year’s Top 40 were selected from among over 100 applications submitted by companies from across Georgia.

“The 2018 Top 40 finalists are an elite group of innovators who represent the very best of Georgia’s Technology community,” said Larry Williams, president & CEO of TAG. “The 2018 Top 40 finalists are shining examples of what makes our State such a hotbed for technology and we applaud them for standing out as leaders in Georgia’s technology community.”

Every year 1 in 8 women are diagnosed with breast cancer.  Seventy percent choose to have breast conservation surgery over mastectomy, yet 1 in 4, hear “I am sorry we didn’t get it all” and have to go back to surgery to have a repeat procedure. These repeat surgeries result in unnecessary patient anxiety, delay in treatment and increase in healthcare costs.  Dilon Devices’ proprietary tissue characterization technology utilizing Radiofrequency (RF) Spectroscopy, is a ground-breaking solution to identifying in the operating room microscopic residual cancer at the surface of the tissue to give surgeons another tool to help the patient avoid a second surgery.  Dune’s first medical device, the MarginProbe System, achieved FDA approval in 2013 for use in breast cancer lumpectomy procedures.  Dune plans to incorporate its platform tissue characterization technology to help with other cancers such as prostate, lung, colo-rectal and liver.  

“Dilon brings objectivity to a procedure that is based mostly upon clinical judgment until now and helps surgeons make the best possible decisions to optimize patient care,” says Lori Chmura, CEO of Dilon. “We are honored that the Technology Association of Georgia recognizes the value in our technology in improving clinical outcomes for patients undergoing breast conserving surgery and are eager to showcase our technology platform during The Summit 2018.”

The Summit 2018 is expected to draw more than 1,500 C-level executives, entrepreneurs, technology professionals and academia to celebrate and recognize Georgia’s technology community.

For more information about TAG and The Summit and to register for the event, visit http://www.tagsummit.com/.